19 April 2022
Kanabo Group PLC
("Kanabo" or the "Company")
Exercise of Options and Total Voting Rights
Kanabo Group Plc (LSE:KNB), a leading innovator and manufacturer of medical cannabis and CBD products, announces that it has issued 290,818 new ordinary shares following the exercise of options granted under its New Share Option Scheme (employees), as detailed in the prospectus dated 29 January 2021.
Application will be made for the ordinary shares to be admitted to the Standard List segment of the Official List and to trading on the main market of the London Stock Exchange plc ("Admission"). It is expected that Admission will become effective and that dealings in the ordinary shares will commence at 8.00am on or around 25 April 2022.
Following Admission, the total issued share capital of the Company will consist of 422,916,056. ordinary shares of 2.5 pence each carrying the right to one vote. There are no shares currently held in treasury. The total number of voting rights in the Company will therefore be 422,916,056 and this figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please visit http://www.kanabogroup.com/ or contact the following:
| Kanabo Group Plc | |
| Assaf Vardimon | Via Vox Markets |
| | |
| Peterhouse Capital Ltd | |
| Eran Zucker / Guy Miller (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
| Lucy Williams / Charles Goodfellow (Corporate Broker) | Tel: +44 (0)20 7469 0930 |
| | |
| Vox Markets (Investor Relations) | |
| Kat Perez |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
